NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

Rhea-AI Summary

NewcelX (Nasdaq: NCEL) updated its corporate presentation to spotlight its flagship Type 1 Diabetes program NCEL-101 and a strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN). The presentation describes integrating NewcelX’s stem-cell-derived islet replacement platform with Eledon’s anti-CD40L antibody tegoprubart to address immune-mediated transplant rejection.

Management will present the updated materials at the upcoming Swiss Biotech Conference to outline the combined development strategy and potential for durable graft survival toward a functional cure for Type 1 Diabetes.

News Market Reaction – NCEL

+6.39% 7.5x vol

15 alerts

+6.39% Session close to close

+24.3% Peak Tracked

-11.5% Trough Tracked

$15.50M Market Cap

7.5x Rel. Volume

In the Apr 20 session, NCEL gained 6.39%, reflecting a notable positive market reaction. Argus tracked a peak move of +24.3% during that session. Argus tracked a trough of -11.5% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 7.5x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.4% in the session following this news. A strong positive reaction aligns with New...

Analysis

The stock moved +6.4% in the session following this news. A strong positive reaction aligns with NewcelX’s efforts to make NCEL-101 the centerpiece of its strategy. Earlier, the initial Eledon collaboration headline saw a -1.08% move, so the current 6.83% gain marks a stronger endorsement of the integrated platform story. Investors may later reassess as clinical data and financing needs evolve, especially given the stock remains 65.18% below its 52-week high.

Key Figures

Price move: 6.83% 52-week range: $1.8299 – $7.64 Tegoprubart experience: >100 patients +5 more

8 metrics

Price move 6.83% 24h change prior to/at news publication

52-week range $1.8299 – $7.64 NCEL 52-week low and high before this news

Tegoprubart experience >100 patients Transplant patients treated in prior tegoprubart studies (Mar 9, 2026 release)

Equity financing $1.35 million Private placement announced on <b>Apr 1, 2026</b>

Equity line $25 million Previously announced equity line to support NCEL-101 and pipeline

Placement price $2.75 per share Private placement pricing at 30% premium to Mar 31, 2026 close

Common shares issued 490,907 shares Shares sold in Apr 1, 2026 private placement

Warrants issued 687,270 warrants Warrants with $3.025 exercise price from Apr 1, 2026 deal

Previous Partnership Reports

1 past event · Latest: Mar 09 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 09	Strategic collaboration	Positive	-1.1%	Announced Eledon partnership combining NCEL-101 with tegoprubart for Type 1 Diabetes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior partnership headline with Eledon produced a mildly negative move despite constructive clinical and regulatory positioning, contrasting with today’s positive reaction.

Recent Company History

Over recent months, NewcelX has repeatedly highlighted Type 1 Diabetes as its core value driver, from positive biomaterials data on stem-cell-derived islets to updated corporate decks and strategic financing. The March 2026 collaboration with Eledon around tegoprubart established NCEL-101’s combination strategy, but the stock dipped 1.08% on that news. Today’s partnership-focused presentation update, again centering NCEL-101 and tegoprubart, aligns with this strategic arc while drawing a stronger positive market response.

Key Terms

stem-cell-derived therapies, islet replacement, anti-cd40l monoclonal antibody, immune-mediated transplant rejection, +2 more

6 terms

stem-cell-derived therapies medical

"a clinical-stage regenerative medicine company developing stem-cell-derived therapies"

Therapies made from stem-cell-derived cells use blank-slate cells that are guided in a lab to become specific human cell types (like heart, nerve, or blood cells) and then used to repair or replace damaged tissue. Investors watch these therapies because they promise large clinical benefits and market potential but also carry high costs, complex manufacturing and strict regulatory hurdles—like buying a high-reward, high-risk long-term project.

islet replacement medical

"NewcelX’s scalable stem-cell-derived islet replacement platform with Eledon’s investigational..."

Islet replacement is a medical treatment that restores the clusters of insulin-producing cells in the pancreas—either by transplanting donor tissue or implanting lab-grown cells—to help the body control blood sugar. Think of it like swapping a dead battery pack in a device so it can run normally again. It matters to investors because clinical results, manufacturing scale and regulatory approval can create or upend markets for diabetes care and strongly influence company value.

anti-cd40l monoclonal antibody medical

"Eledon’s investigational anti-CD40L monoclonal antibody tegoprubart, a targeted immune-modulation..."

An anti-CD40L monoclonal antibody is a lab-made protein designed to stick to the CD40 ligand, a molecule that helps immune cells communicate and drive inflammation. By blocking that signal it can dial down an overactive immune response, which might treat autoimmune disease, prevent organ rejection or modify inflammatory conditions. For investors, these drugs matter because clinical results, safety and regulatory decisions determine whether a candidate becomes a viable commercial treatment with significant market and revenue implications.

immune-mediated transplant rejection medical

"tegoprubart, a targeted immune-modulation therapy designed to prevent immune-mediated transplant rejection."

An immune-mediated transplant rejection occurs when a recipient’s immune system recognizes a donated organ or tissue as foreign and attacks it, damaging or destroying the transplant. Think of the immune system as a security team that sometimes mistakes a welcomed guest for an intruder; preventing or treating these attacks is crucial because rejection determines transplant survival, drives demand for immunosuppressive drugs and monitoring tools, and influences healthcare costs and regulatory outcomes relevant to investors.

graft survival medical

"represents a promising strategy to support durable graft survival and advance the development..."

Graft survival measures how long a transplanted organ, tissue, or engineered product continues to work in the recipient without failing or needing removal. Think of it as the lifespan of a replacement part inside the body. For investors, graft survival is a key clinical and commercial signal: longer survival reduces repeat procedures and ongoing care, improves patient outcomes, and supports stronger reimbursement, market adoption, and the valuation of therapies, devices, or services tied to transplantation.

type 1 diabetes medical

"advance the development of a potential functional cure for Type 1 Diabetes."

An autoimmune condition in which the pancreas stops producing insulin, a hormone that lets the body use sugar for energy; without insulin people must manage blood sugar with injections, pumps, or other therapies. For investors, it matters because the lifelong need for medicines, devices, and monitoring creates steady demand, influences healthcare spending and reimbursement decisions, and drives clinical trials and regulatory activity in the diabetes treatment market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company’s development strategy.

The updated presentation outlines the integration of NewcelX’s scalable stem-cell-derived islet replacement platform with Eledon’s investigational anti-CD40L monoclonal antibody tegoprubart, a targeted immune-modulation therapy designed to prevent immune-mediated transplant rejection. NewcelX believes this combined approach represents a promising strategy to support durable graft survival and advance the development of a potential functional cure for Type 1 Diabetes.

Management plans to present the updated presentation to investors and industry participants at the upcoming Swiss Biotech Conference, where NewcelX will present its evolving strategy and development vision for the Type 1 Diabetes program.

About NewcelX

NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.

Social Media: LinkedIn, Facebook, X, Instagram

Website: www.newcelx.com 

Forward-Looking Statements

This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses how the collaboration represents a promising strategy to support durable graft survival and advance the development of a potential functional cure for Type 1 Diabetes. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays in developing or introducing new technologies, products, or applications; and competitive pressures that could reduce market share or pricing. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission ("SEC") and available at www.sec.gov, as well as in subsequent filings made by NewcelX, including under the heading "Risk Factors" in its proxy statement/prospectus filed with the SEC on November 6, 2025.

Investor & Media Contacts

Sarah Bazak, Investors relations
InvestorRelations@newcelx.com

FAQ

What does NewcelX announce about its Type 1 Diabetes program NCEL-101 (NCEL) on April 20, 2026?

NewcelX updated its corporate presentation to highlight NCEL-101 as its flagship Type 1 Diabetes program. According to the company, the presentation emphasizes NCEL-101’s role within a combined cell-replacement and immune-modulation strategy with Eledon’s tegoprubart antibody.

What is the strategic collaboration between NewcelX (NCEL) and Eledon Pharmaceuticals (ELDN)?

The collaboration pairs NewcelX’s stem-cell-derived islet replacement platform with Eledon’s anti-CD40L antibody tegoprubart. According to the company, the approach aims to reduce immune-mediated transplant rejection and support durable graft survival in Type 1 Diabetes.

How will the updated NewcelX (NCEL) presentation be shared with investors at the Swiss Biotech Conference?

NewcelX will present the updated corporate presentation at the Swiss Biotech Conference to investors and industry participants. According to the company, management plans to discuss the evolving strategy and development vision for the Type 1 Diabetes program during the conference presentation.

Does the NewcelX and Eledon collaboration (NCEL, ELDN) include clinical results or regulatory approvals?

The announcement highlights integration of platforms but does not report clinical readouts or regulatory approvals. According to the company, the presentation focuses on strategy and platform integration rather than disclosing new trial results or approvals.

What therapeutic mechanism does Eledon’s tegoprubart provide in the NewcelX (NCEL) strategy?

Tegoprubart is described as an investigational anti-CD40L monoclonal antibody intended to modulate immune responses. According to the company, it is being paired with cell-replacement therapy to reduce immune-mediated transplant rejection risk for islet grafts.

What is the intended goal of combining NewcelX’s islet platform with Eledon’s antibody for NCEL-101?

The combined approach is intended to support durable graft survival and advance toward a potential functional cure for Type 1 Diabetes. According to the company, the strategy couples scalable cell-replacement with targeted immune modulation to improve transplant outcomes.